Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β(1), and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia

BACKGROUND: The outcome for chronic myelogenous leukemia (CML) patients presented in the chronic phase has changed dramatically since the introduction of tyrosine kinase inhibitor (TKI) therapy. Notably, an increased incidence of large granular lymphocytes (LGLs), which is related to immunological c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Shosaku, Ito, Tomoki, Satake, Atsushi, Ishii, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305157/
https://www.ncbi.nlm.nih.gov/pubmed/30588140
http://dx.doi.org/10.2147/JBM.S187005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305157/
https://www.ncbi.nlm.nih.gov/pubmed/30588140
http://dx.doi.org/10.2147/JBM.S187005

Ejemplares similares